The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Zante Greg since 2023.
This trader's CIK number is 1264949.
At the time of last reporting, Zante Greg was the Chief Financial Officer of Viking Therapeutics, Inc.. (stock ticker symbol VKTX).
Also see all insider trading activities at Viking Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | VKTX | 0 | $0 | 54,575 | $2,281,916 | 0 | $0 |
| 2024 | VKTX | 0 | $0 | 229,579 | $16,496,006 | 128,250 | $792,858 |
| 2023 | VKTX | 0 | $0 | 267,279 | $4,695,611 | 230,000 | $1,531,100 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-07-03 | VKTX | Sale | 4,266 | 27.76 | 118,428 |
| 2025-01-06 | VKTX | Sale | 50,309 | 43.00 | 2,163,488 |
| 2024-10-28 | VKTX | Option Ex | 94,001 | 6.69 | 629,148 |
| 2024-10-28 | VKTX | Sale | 131,687 | 78.19 | 10,296,738 |
| 2024-07-30 | VKTX | Sale | 16,136 | 57.79 | 932,547 |
| 2024-05-03 | VKTX | Sale | 66,756 | 74.87 | 4,998,221 |
| 2024-05-03 | VKTX | Option Ex | 34,249 | 4.78 | 163,710 |
| 2024-01-04 | VKTX | Sale | 15,000 | 17.90 | 268,500 |
| 2023-04-17 | VKTX | Option Ex | 7,500 | 13.07 | 98,025 |
| 2023-04-17 | VKTX | Sale | 7,500 | 20.00 | 150,000 |
| 2023-04-11 | VKTX | Option Ex | 56,295 | 5.78 | 325,553 |
| 2023-04-12 | VKTX | Option Ex | 41,544 | 6.79 | 281,876 |
| 2023-04-11 | VKTX | Sale | 56,295 | 18.00 | 1,013,535 |
| 2023-04-12 | VKTX | Sale | 41,544 | 18.00 | 747,792 |
| 2023-04-03 | VKTX | Option Ex | 30,911 | 7.77 | 240,178 |
| 2023-03-30 | VKTX | Sale | 131,029 | 17.00 | 2,227,886 |
| 2023-04-03 | VKTX | Sale | 30,911 | 18.00 | 556,398 |
| 2023-03-30 | VKTX | Option Ex | 93,750 | 6.25 | 585,468 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Zante Greg (Chief Financial Officer of Viking Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.